When and how can nephrologists treat hepatitis C virus infection in dialysis patients?-Reference-Cited by-同舟云学术

When and how can nephrologists treat hepatitis C virus infection in dialysis patients?

Published:2017-09-18 Issue:1 Volume:31 Page:26-36
ISSN:0894-0959
Container-title:Seminars in Dialysis
language:en
Short-container-title:Semin Dial

Author:

Davis Maya I.¹,Chute Donald F.²,Chung Raymond T.²,Sise Meghan E.¹

Affiliation:

1. Division of Nephrology; Department of Medicine; Massachusetts General Hospital; Boston MA USA

2. Gastrointestinal Unit; Department of Medicine; Massachusetts General Hospital; Boston MA USA

Publisher

Wiley

Subject

Nephrology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/sdi.12650/fullpdf

Reference84 articles.

1. Division of Viral Hepatitis and National Center for HIV/AIDS VH, STD, and TB Prevention Surveillance for Viral Hepatitis-United States, 2015 https://www.cdc.gov/hepatitis/statistics/2015surveillance/commentary.htm

2. Natural history of liver fibrosis progression in patients with chronic hepatitis C;Poynard;The Lancet,1997

3. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score;Virlogeux;J Viral Hepatitis,2014

4. Cellular and molecular biology of HCV infection and hepatitis;Tang;Clin Sci,2009

5. Hepatitis C virus infection;Lauer;N Engl J Med,2001

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are We on the Right Track for HCV Micro-Elimination? HCV Management Practices in Dialysis Centers in Poland—A National Cross-Sectional Survey;Journal of Clinical Medicine;2023-04-04

2. Transplantation of Organs from Hepatitis C Virus-Positive Donors under Direct-Acting Antiviral Regimens;Journal of Clinical Medicine;2022-01-31

3. Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end‐stage renal disease on maintenance haemodialysis;Liver International;2021-03-17

4. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1–6 infection: A systematic review and meta-analysis;International Journal of Antimicrobial Agents;2019-12

5. Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors;Current Opinion in Organ Transplantation;2019-06